Art

J-GLOBAL ID：202202272247085749   Reference number：22A1027879

Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies

免疫抑制腫瘍微小環境のキープレーヤーと新たな治療戦略【JST・京大機械翻訳】

Author (8)： Park Kevin (1Department of Medicine, Division of Hematology/Oncology, Los Angeles, CA, United States) ,  Park Kevin (2VA Greater Los Angeles Healthcare System, University of California, Los Angeles (UCLA), Los Angeles, CA, United States) ,  Veena Mysore S. (1Department of Medicine, Division of Hematology/Oncology, Los Angeles, CA, United States) ,  Veena Mysore S. (2VA Greater Los Angeles Healthcare System, University of California, Los Angeles (UCLA), Los Angeles, CA, United States) ,  Shin Daniel Sanghoon (1Department of Medicine, Division of Hematology/Oncology, Los Angeles, CA, United States) ,  Shin Daniel Sanghoon (2VA Greater Los Angeles Healthcare System, University of California, Los Angeles (UCLA), Los Angeles, CA, United States) ,  Shin Daniel Sanghoon (3Molecular Biology Institute, Los Angeles, CA, United States) ,  Shin Daniel Sanghoon (4Jonsson Comprehensive Cancer Center, Los Angeles, CA, United States)
Material： Frontiers in Cell and Developmental Biology (Web)
Volume： 10  Page： 830208  Publication year： 2022 
JST Material Number： U7062A  ISSN： 2296-634X  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： The tumor microenvironment (TM...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=22A1027879&from=J-GLOBAL&jstjournalNo=U7062A") }}

Thesaurus term： *tumor ,  tumor cell ,  biological preparation ,  drug therapy ,  clinical trial ,  *immunosuppression ,  combination therapy ,  monoclonal antibody ,  targeting ,  *therapeutic planning ,  VEGF ,  chemokine ,  tumor immunity ,  advanced cancer ,  molecular targeting drug
Semi thesaurus term： 癌治療 ,  免疫チェックポイント阻害剤 , 【Automatic Indexing@JST】

Author keywords (6)： tumor microenvironment ,  cancer ,  immune escape ,  immune checkpoint inhibitors ,  immunotherapy ,  clinical trials

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Reference (273)：

• Abou KhouzamR., GouthamH. V., ZaarourR. F., ChamseddineA. N., FrancisA., BuartS., et al (2020). Integrating Tumor Hypoxic Stress in Novel and More Adaptable Strategies for Cancer Immunotherapy. Semin. Cancer Biol. 65, 140-154. doi: 10.1016/j.semcancer.2020.01.003
• AcharyaN., Sabatos-PeytonC., AndersonA. C. (2020). Tim-3 Finds its Place in the Cancer Immunotherapy Landscape. J. Immunother. Cancer 8, e000911. doi: 10.1136/jitc-2020-000911
• ADC Therapeutics S.A (2021). A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients with Selected Advanced Solid Tumors. clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03621982 (Accessed November 21, 2021). doi: 10.1136/jitc-2020-000911
• Alligator Bioscience (2021). A First-In-Human, Multicenter, Open-Label, Phase 1 Study in Patients with Advanced And/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015. clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03782467 (Accessed November 25, 2021). doi: 10.1136/jitc-2020-000911
• AnsellS. M., MarisM. B., LesokhinA. M., ChenR. W., FlinnI. W., SawasA., et al (2021). Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clin. Cancer Res. 27, 2190-2199. doi: 10.1158/1078-0432.CCR-20-3706

Terms in the title (5)： 免疫抑制 ,  腫瘍微小環境 ,  キー ,  プレーヤー ,  治療戦略